Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

Amedeo Lonardo,Stefano Ballestri,Alessandro Mantovani,Giovanni Targher,Fernando Bril

DOI: https://doi.org/10.3390/metabo14010040

IF: 4.1

2024-01-09

Metabolites

Abstract:This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated steatohepatitis (MASH), is a systemic metabolic disorder featuring both adverse hepatic and extrahepatic outcomes. In recent years, several NASH trials have failed to identify effective pharmacological treatments and, therefore, lifestyle changes are the cornerstone of therapy for NASH. with this context, we analyze the epidemiological burden of NASH and the possible pathogenetic factors involved. These include genetic factors, insulin resistance, lipotoxicity, immuno-thrombosis, oxidative stress, reprogramming of hepatic metabolism, and hypoxia, all of which eventually culminate in low-grade chronic inflammation and increased risk of fibrosis progression. The possible explanations underlying the failure of NASH trials are also accurately examined. We conclude that the high heterogeneity of NASH, resulting from variable genetic backgrounds, exposure, and responses to different metabolic stresses, susceptibility to hepatocyte lipotoxicity, and differences in repair-response, calls for personalized medicine approaches involving research on noninvasive biomarkers. Future NASH trials should aim at achieving a complete assessment of systemic determinants, modifiers, and correlates of NASH, thus adopting a more holistic and unbiased approach, notably including cardiovascular–kidney–metabolic outcomes, without restricting therapeutic perspectives to histological surrogates of liver-related outcomes alone.

biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is related to the selection of endpoint indicators in non - alcoholic steatohepatitis (NASH) clinical trials. Specifically, the authors explored NASH as a systemic metabolic disorder that not only affects liver health but also involves a variety of extra - hepatic adverse consequences. In recent years, despite numerous NASH clinical trials, most have failed to find effective drug treatments, resulting in lifestyle changes becoming the main means of treating NASH. Therefore, the paper analyzed the epidemiological burden of NASH and its possible pathogenic factors, and deeply examined the possible reasons for the failure of NASH clinical trials. The author believes that the high heterogeneity of NASH (caused by different genetic backgrounds, exposure and response to different metabolic stresses, differences in hepatocyte lipotoxicity sensitivity and repair responses) requires a personalized medical approach, especially the study of non - invasive biomarkers. Future NASH trials should aim to comprehensively evaluate the systemic determinants, modifiers and related factors of NASH, using a more comprehensive and unbiased approach, not limited to histological surrogate markers of liver - related outcomes as a treatment perspective.